Home
 /
Papers
 /
Molecular Biology
 /
Molecular surface mimicry enables CRBN to target G3BP2 for degradation
Preprint
Open access
Top 1% · Validated by QED

Molecular surface mimicry enables CRBN to target G3BP2 for degradation

Stefano Annunziato, Chao Quan, Etienne J. Donckele +30 more
May 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.04.30.651496
99
%
QED Score
QED Impressions

By revealing that CRBN mimics a target's endogenous partner to recruit G3BP2 through its LON domain, this work overturns the G-loop paradigm and unlocks a vastly expanded protein repertoire for molecular glue degraders.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

The CRBN neosubstrate G3BP2 bypasses the canonical G-loop recognition mechanism and is recruited through a novel molecular surface mimicry mechanism in which CRBN's LON domain mimics the natural G3BP2 binding partner USP10, repurposing a preexisting PPI hotspot on the target protein's NTF2L domain to enable MRT-5702-mediated degradation through an unconventional binding interface that is structurally and mechanistically distinct from all previously characterized CRBN neosubstrates.

See full analysis
Main Claim 1 –

MRT-5702 Induces CRBN-Mediated Recruitment and Degradation of G3BP2

Supporting evidence

  • MRT-5702 Selectively Drives CRBN–G3BP2 Ternary Complex Formation
  • G3BP2 NTF2L Domain Is Necessary and Sufficient for Degradation
  • Purified G3BP2 NTF2L Forms CRBN–MRT-5702 Ternary Complex In Vitro
Main Claim 2 –

CRBN Mimics Endogenous Partner to Bind G3BP2 PPI Hotspot

Supporting evidence

  • Predicted CRBN–G3BP2 Interface Residues Are Required for Ternary Complex
Main Claim 3 –

Cryo-EM Confirms G3BP2 Hotspot Binding to CRBN F150–I152

Supporting evidence

  • Only (S,S) MRT-5702D Stereoisomer Triggers G3BP2 Degradation
  • (S,S) MRT-5702D Best Fits Cryo-EM Ligand Density
  • CRBN LON-Loop Flexibility Enhances Complementarity for G3BP2 Binding
  • G3BP2 Bypasses Canonical CRBN Site via LON Domain Interface

Abstract

Molecular glue degraders (MGDs) are small molecule compounds that repurpose the ubiquitin-proteasome system to induce degradation of challenging therapeutic targets. Clinically effective MGDs bind cereblon (CRBN), a substrate receptor of the Cullin-4/RING E3 ubiquitin ligase (CRL4CRBN), and impose a gain-of-function activity to recruit, ubiquitinate and degrade so-called neosubstrate proteins. Known neosubstrates bind the CRBN/MGD neosurface on the CRBN CULT domain through a structural G-loop recognition motif that mimics contacts of a natural CRBN degron. Here we report the binding mode of G3BP2, a CRBN neosubstrate that bypasses the G-loop requirement by engaging an unconventional binding site on the CRBN LON domain. The MGD-induced ternary complex interface does not resemble known protein-protein interactions (PPI) with CRBN. Instead, CRBN mimics an endogenous binding partner of G3BP2 and repurposes a preexisting PPI hotspot on the target protein. Our findings provide a novel generalizable concept for the rationalization of unconventional neosubstrate binding modes on CRBN, demonstrate unprecedented potential for the reprogrammability of this substrate receptor by MGDs, and offer opportunities for rational expansion of the target repertoire accessible to this modality.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?